Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 213377
Company: ANNORA PHARMA

Products on ANDA 213377

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 213377

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/19/2020	ORIG-1	Approval		STANDARD		Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
01/31/2024	SUPPL-4	Labeling-Package Insert		Label is not available on this site.
09/12/2023	SUPPL-2	Labeling-Package Insert		Label is not available on this site.

Therapeutic Equivalents for ANDA 213377

MESALAMINE

SUPPOSITORY;RECTAL; 1GM
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CANASA	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	Yes	AB	021252	ABBVIE
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	205654	ACTAVIS MID ATLANTIC
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	208362	AMRING PHARMS
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	213377	ANNORA PHARMA
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	204354	MYLAN
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	207448	PHARM SOURCING
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	202065	SANDOZ
MESALAMINE	MESALAMINE	1GM	SUPPOSITORY;RECTAL	Prescription	No	AB	208953	ZYDUS PHARMS